Advertisement

CNS Drugs

, Volume 25, Issue 6, pp 503–509 | Cite as

Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

  • Luigi MazzoneEmail author
  • Laura Reale
  • Valeria Mannino
  • Mariadonatella Cocuzza
  • Benedetto Vitiello
Short Communication

Abstract

Objectives: Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine.

Methods: The records of all the children and adolescents treated with atomoxetine at a university clinic in Catania, Italy, over a 3-year period were examined. A total of 55 clinically referred children and adolescents (aged 5–15 years, 53 males) with ADHD were treated with atomoxetine (10–110mg/day; mean: 1.28 mg/kg/day) for a period ranging from 2 to 168 weeks (mean: 57.3±SD 39.4, median: 56). The IQ was assessed as part of the diagnostic evaluation prior to starting treatment. During treatment, clinical outcome was rated on the Clinical Global Impression-Improvement (CGI-I) and CGI-Severity (CGI-S) scales.

Results: The IQ ranged from 43 to 117 (mean: 80.6 ± SD 18.6, median: 84). The IQ and final CGI-I scores were negatively correlated (r=−0.68; p<0.01). Children and adolescents with an IQ <85 were less likely to be responders (defined as a final CGI-I score of 1 or 2) than children and adolescents with an IQ ≥85 (20.71% vs 76.9%; p< 0.001). None of the patients discontinued atomoxetine due to adverse effects, while treatment was discontinued in 20 subjects due to a lack of efficacy or ambivalence of parents about pharmacological treatment.

Conclusions: Atomoxetine appears to be less effective in children and adolescents with an IQ <85 than in children and adolescents in the average range of cognitive functioning. This difference is not accounted for by differences in the severity of ADHD symptoms, co-morbidity or reduced tolerability to the medication. These findings suggest that, in order to be fully informative, clinical trials of medications for ADHD should also include children and adolescents functioning in the borderline and cognitive disability range.

Keywords

Autism Spectrum Disorder Methylphenidate Oppositional Defiant Disorder ADHD Symptom Intellectual Disability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Luigi Mazzone and Laura Reale contributed equally to this work in terms of realization of the study, data analysis and paper writing. Valeria Mannino and Mariadonatella Cocuzza collected the data, and Benedetto Vitiello contributed to the design of the study, supervised statistical analysis and helped in the theoretical interpretation of the results. This study was funded by the Division of Child Neurology and Psychiatry of the University of Catania, Catania, Italy. Dr Mannino received educational travel funds by Eli Lilly. The other authors (LM, LR, BV) have no relevant financial disclosures.

References

  1. 1.
    Michelson D, Faries D, Wernicke J, et al., Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83PubMedCrossRefGoogle Scholar
  2. 2.
    Newcorn JH, Kratochvil CJ, Allen AJ, et al., Atomoxetine/ Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008 Jun; 165(6): 721–30PubMedCrossRefGoogle Scholar
  3. 3.
    Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychology 2003; 71(3): 540–52CrossRefGoogle Scholar
  4. 4.
    Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 2010; 20(3): 197–203PubMedCrossRefGoogle Scholar
  5. 5.
    Fernandez-Jaen A, Fernandez-Mayoralas DM, Perez BC, et al. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. Pediatr Neurol 2010; 43(5): 341–7PubMedCrossRefGoogle Scholar
  6. 6.
    Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16(5): 599–610PubMedCrossRefGoogle Scholar
  7. 7.
    Troost PW, Steenhuis MP, Tuyman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006; 16(5): 611–9PubMedCrossRefGoogle Scholar
  8. 8.
    Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1196–205PubMedCrossRefGoogle Scholar
  9. 9.
    Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980–8PubMedCrossRefGoogle Scholar
  10. 10.
    Guy W, editor. ECDEU assessment manual for psychopharmacology: publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare, 1996: 218–22Google Scholar
  11. 11.
    Wechsler D. Wechsler intelligence scale for children, WISC-III. 3rd ed. New York (NY): Psychological Corporation, 1991Google Scholar
  12. 12.
    Swanson JM, Sandman CA, Deutsch C, et al. Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. Pediatrics 1983; 72: 49–55Google Scholar
  13. 13.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2002Google Scholar
  14. 14.
    Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of the three aggregated studies. J Child Adolesc Psychopharmacol 2003; 13: 28–40CrossRefGoogle Scholar
  15. 15.
    Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62: 1266–74CrossRefGoogle Scholar
  16. 16.
    Handen BL, Breaux AM, Gosling A, et al. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics 1990; 86(6): 922–30PubMedGoogle Scholar
  17. 17.
    Aman MG, Marks RE, Turbott SH, et al. Methylphenidate and thioridazine in the treatment of intellectually sub-average children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 1991; 30(5): 816–24PubMedGoogle Scholar
  18. 18.
    Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27(5): 699–711PubMedCrossRefGoogle Scholar
  19. 19.
    Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cereb Cortex 2007 Sep; 17 Suppl. 1: i161–70PubMedCrossRefGoogle Scholar
  20. 20.
    Marshburn EC, Aman MG. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992; 22: 357–73PubMedCrossRefGoogle Scholar
  21. 21.
    Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42: 1443–50PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Luigi Mazzone
    • 1
    Email author
  • Laura Reale
    • 1
  • Valeria Mannino
    • 1
  • Mariadonatella Cocuzza
    • 1
  • Benedetto Vitiello
    • 2
  1. 1.Division of Child Neurology and Psychiatry, Department of PediatricsUniversity of CataniaCataniaItaly
  2. 2.Child and Adolescent Treatment and Preventive Intervention Research BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations